Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis.

BACKGROUND The caprazamycin derivative, CPZEN-45 has previously demonstrated antitubercular activity against Mycobacterium tuberculosis H37Rv. Here, the authors report a basic biopharmaceutical characterization of the compound focusing on in vitro permeability and cytotoxicity, with respect to the suitability of CPZEN-45 hydrochloride for inhalation treatment of tuberculosis. RESULTS MTT assays confirmed that CPZEN-45 HCl had no acute cytotoxic effects up to 3 mg/ml. In transport studies, apparent permeability coefficients of CPZEN-45 HCl across Calu-3 monolayers in absorptive and secretive directions were 0.43 ± 0.20 × 10(-6) cm/s and 0.38 ± 0.12 × 10(-6) cm/s, respectively. Across ATI-like monolayers, apparent permeability values were 12.10 ± 4.31 × 10(-6) cm/s and 8.50 ± 1.83 × 10(-6) cm/s. CPZEN-45 HCl formed colloidal complexes at concentrations above 0.38 mg/ml; however, these complexes were not micelles, as assessed by Orange OT encapsulation assay. CONCLUSION CPZEN-45 is an interesting new drug candidate with potential to be used in aerosol therapy of tuberculosis.

[1]  R. Mehta,et al.  Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study , 2013, International journal of chronic obstructive pulmonary disease.

[2]  Dae-Duk Kim,et al.  Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. , 2013, International journal of pharmaceutics.

[3]  J. Engohang-Ndong,et al.  Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment , 2012, Expert opinion on investigational drugs.

[4]  C. Ehrhardt,et al.  Transport of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) in human respiratory epithelial cells. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  C. Ehrhardt,et al.  Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. , 2012, Therapeutic delivery.

[6]  J. O’Grady,et al.  Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. , 2012, The Journal of infectious diseases.

[7]  M. Gonzalez-Juarrero,et al.  Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery , 2012, Antimicrobial Agents and Chemotherapy.

[8]  A. Healy,et al.  In Vitro and In Vivo Characterisation of PEG-Lipid-Based Micellar Complexes of Salmon Calcitonin for Pulmonary Delivery , 2012, Pharmaceutical Research.

[9]  L. Zakharova,et al.  Self-assembling systems based on amphiphilic alkyltriphenylphosphonium bromides: elucidation of the role of head group. , 2012, Journal of colloid and interface science.

[10]  C. Ehrhardt,et al.  Nanoparticles attenuate P-glycoprotein/MDR1 function in A549 human alveolar epithelial cells. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  G. Cavallaro,et al.  Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids. , 2011, International journal of pharmaceutics.

[12]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[13]  J. Sadoff,et al.  Update on research and development pipeline: tuberculosis vaccines. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  C. Bosquillon,et al.  Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs? , 2010, Journal of pharmaceutical sciences.

[15]  A. Hickey,et al.  Inhaled Drug Delivery for Tuberculosis Therapy , 2009, Pharmaceutical Research.

[16]  C. Ehrhardt,et al.  In vitro cell culture models for the assessment of pulmonary drug disposition , 2008 .

[17]  Malgorzata Smola,et al.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases , 2008, International journal of nanomedicine.

[18]  R. Peters,et al.  From fluorescence nanoscopy to nanoscopic medicine. , 2008, Nanomedicine.

[19]  M. Gumbleton,et al.  P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers , 2007, Cell and Tissue Research.

[20]  A. Wanner,et al.  Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. , 2007, American journal of respiratory cell and molecular biology.

[21]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[22]  E. Rieber,et al.  Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells , 2006, Cell and Tissue Research.

[23]  Ben Forbes,et al.  Human respiratory epithelial cell culture for drug delivery applications. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  H. Naganawa,et al.  Caprazamycins, Novel Lipo-nucleoside Antibiotics, from Streptomyces sp. , 2005, The Journal of Antibiotics.

[25]  R. Pandey,et al.  Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, The Journal of antimicrobial chemotherapy.

[26]  H. Naganawa,et al.  Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. , 2003, The Journal of antibiotics.

[27]  K. Audus,et al.  P-glycoprotein efflux pump expression and activity in Calu-3 cells. , 2001, Journal of pharmaceutical sciences.

[28]  D. Hokey,et al.  Aerosol vaccines for tuberculosis: a fine line between protection and pathology. , 2011, Tuberculosis.

[29]  M. Gumbleton,et al.  Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. , 2011, Advanced drug delivery reviews.

[30]  P. Colombo,et al.  Inhaled drug therapy for treatment of tuberculosis. , 2011, Tuberculosis.